HDQ-P1 Xenograft Model Service for Breast Cancer

The HDQ-P1 xenograft model delivers a highly specialized in vivo translational platform designed to evaluate therapeutic candidates targeting aggressive, basal-like triple-negative breast cancers with distinct E-cadherin deficiencies. Alfa Cytology provides a comprehensive, end-to-end HDQ-P1 xenograft model service, combining optimized cell preparation methodologies with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of HDQ-P1 Xenograft Model for Breast Cancer

The HDQ-P1 cell line is a well-characterized human mammary carcinoma model that represents the basal-like, triple-negative breast cancer (TNBC) molecular subtype. Originally derived from a primary human breast tumor, HDQ-P1 is molecularly defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. A notable genomic feature of the HDQ-P1 model is its altered expression or mutational status of key cellular adhesion molecules, such as E-cadherin (CDH1), which plays a significant role in mediating epithelial-to-mesenchymal transition (EMT), high invasive potential, and metastatic progression. This distinct genetic background makes the HDQ-P1 model a critical preclinical tool for evaluating novel targeted small molecules, exploring epigenetic modifiers, and validating therapeutic strategies designed to counteract aggressive TNBC proliferation.

When established in vivo as a xenograft in immunocompromised mice, HDQ-P1 cells form solid tumors that faithfully preserve the complex histopathological architecture and genomic features of clinical receptor-negative breast malignancies. The model exhibits steady, reliable engraftment rates and highly predictable growth kinetics. This consistent tumor development provides researchers with a robust and dependable therapeutic testing window for preclinical efficacy screenings, biomarker analysis, and pharmacodynamic (PK/PD) assessments.

Cell Line Information: HDQ-P1

The HDQ-P1 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary triple-negative receptor status and invasive genomic signatures upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HDQ-P1 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HDQ-P1 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in basal-like triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HDQ-P1 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HDQ-P1 xenograft model:

• Cell Culture & Quality Control: HDQ-P1 cells are cultivated in optimized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HDQ-P1 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. HDQ-P1 Xenograft Model Construction Workflow

Case Study - HDQ-P1 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HDQ-P1 xenograft model was successfully utilized to evaluate the efficacy of a novel targeted agent focusing on cell signaling pathways in triple-negative breast cancer. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Why Choose Alfa Cytology?

Choosing the right partner for your basal-like triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, basal-like triple-negative breast cancer using the robust HDQ-P1 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.